Podcast: Multiple ‘Centers of Excellence’ At US FDA Could Create Review Inefficiencies – Jenkins

FDA’s outgoing head of new drug review cautions against duplicating Oncology ‘Center of Excellence’ model across multiple therapeutic areas, advocating for a more ‘balanced portfolio’ in structuring review operations; other topics during podcast interview include Jenkins’ future plans in drug regulation and one major safety decision that turned out differently than expected.

FDA entrance sign 2016

The Food & Drug Administration’s Oncology “Center of Excellence” may be an efficient way to review new cancer treatments, but it is not a model that should be replicated for every therapeutic category across the agency, Office of New Drugs Director John Jenkins, MD, said during an exit interview podcast ahead of his planned departure from the agency on Jan. 6.

“There is a lot of history behind how FDA is organized, and there is some rationale about how FDA is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership